NANJING, China, Sept. 22 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (“Simcere” or the “Company”), a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China, today announced that Jiangsu Yanshen Biological Technology Stock Co., Ltd (“Jiangsu Yanshen”), in which Simcere holds a 37.5% stake, was awarded a new drug certificate and production license from China’s State Food and Drug Administration (SFDA) on September 18 for Jiangsu Yanshen’s H1N1 vaccine. Of the eleven flu vaccine manufacturers in China, Jiangsu Yanshen is one of six currently licensed to produce the H1N1 vaccine.
“We are delighted that Jiangsu Yanshen has been awarded a new drug certificate and production license for the H1N1 flu vaccine,” commented Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere Pharmaceutical Group. “Simcere’s investment in Jiangsu Yanshen is an important part of our strategy to become a leader in China’s fast growing biopharmaceutical industry.”
Safe Harbor Statement
This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions. These forward looking statements are based upon management’s current views and expectations with respect to future events and are not a guarantee of future performance. Furthermore, these statements are, by their nature, subject to a number of risks and uncertainties that could cause actual performance and results to differ materially from those discussed in the forward-looking statements as a result of a number of factors. Further information regarding these and other risks is included in Simcere’s filing with the U.S. Securities and Exchange Commission at http://www.sec.gov . Simcere does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group is a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells anti-infective medication, anti-cancer medication and stroke management medication. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .
SOURCE Simcere Pharmaceutical Group
CONTACT: Investor and Media Contacts: ir@simcere.com; In Nanjing: Frank
Zhao, Chief Financial Officer of Simcere Pharmaceutical Group, +86-25-8556-
6666 x8818; In Beijing: Ruirui Jiang of Brunswick Group, +86-10-6566-2256;
In the United States: Kate Tellier of Brunswick Group LLC, +1-212-333-3810;
In Hong Kong: Joseph Lo Chi-Lun of Brunswick Group, +852-3512-5000
Web site: http://www.simcere.com/
